Venus Remedies Ltd Hits Lower Circuit Amid Heavy Selling Pressure

Intraday Price Movement and Volatility

The stock of Venus Remedies Ltd (Series BE) opened the day with cautious trading but soon succumbed to sustained selling pressure. It recorded an intraday low of ₹685.55, marking a 5.0% decline from previous levels, before settling at ₹702.00. This represented a maximum daily loss of 4.79%, a significant drop for a stock that had previously maintained a relatively stable trajectory.

Intraday volatility was notably high, with a calculated figure of 6.27% based on the weighted average price, reflecting sharp price swings throughout the session. The weighted average price itself indicated that the majority of traded volume clustered near the day’s low, signalling strong bearish momentum and a lack of buying interest at higher levels.

Trading Volumes and Liquidity

Trading volumes were moderate, with total traded volume reaching approximately 17,499 shares (0.17499 lakhs). The turnover for the day stood at ₹1.21 crore, which, while not exceptionally high, was sufficient to reflect genuine market activity rather than sporadic trades. The stock’s liquidity remains adequate for trade sizes up to ₹0.05 crore, based on 2% of the five-day average traded value, but the current session’s volume was below average, suggesting some investors were hesitant to engage amid the sharp price fall.

Delivery volumes have shown a marked increase recently, with 2,430 shares delivered on 9 Jan 2026, a rise of 95.89% compared to the five-day average. This uptick in investor participation contrasts with the current session’s selling pressure, indicating that some investors may have been offloading positions in response to deteriorating market sentiment.

Comparison with Sector and Market Benchmarks

Venus Remedies Ltd’s performance on 12 Jan 2026 was notably weaker than its sector peers and the broader market indices. The Pharmaceuticals & Biotechnology sector declined by 1.13% on the day, while the Sensex fell by a modest 0.47%. The stock’s 2.85% one-day return lagged behind both benchmarks, underscoring the severity of the sell-off relative to the industry and market.

This underperformance is particularly concerning given the company’s recent Mojo Score of 72.0 and a Mojo Grade of Buy, which was downgraded from Strong Buy on 6 Jan 2026. The downgrade reflects a reassessment of the company’s near-term prospects, possibly influenced by emerging market pressures and valuation concerns.

Technical Indicators and Moving Averages

From a technical standpoint, Venus Remedies Ltd’s share price remains above its 50-day, 100-day, and 200-day moving averages, indicating a longer-term uptrend. However, the stock is trading below its 5-day and 20-day moving averages, signalling short-term weakness and potential bearish momentum. This divergence suggests that while the medium- to long-term outlook may retain some positivity, immediate market sentiment is decidedly negative.

The stock’s price band of ₹5 and the maximum permissible daily price change of -2.72% were breached, triggering the lower circuit limit of -19.6 points. This automatic trading halt mechanism was activated to curb excessive volatility and prevent disorderly market conditions, highlighting the intensity of the selling pressure.

Market Capitalisation and Company Profile

Venus Remedies Ltd is classified as a micro-cap company with a market capitalisation of approximately ₹937.03 crore. Operating within the Pharmaceuticals & Biotechnology industry, the company faces competitive pressures and regulatory challenges that can impact investor confidence. The recent price action may reflect concerns over sectoral headwinds or company-specific developments, though no explicit news was reported on the day.

Investor Sentiment and Outlook

The sharp decline and circuit hit reflect a wave of panic selling, likely driven by a combination of profit-booking and cautious positioning ahead of upcoming sector developments. The unfilled supply at lower price levels suggests that sellers outnumbered buyers significantly, exacerbating the downward pressure.

Despite the negative price action, the company’s Mojo Grade of Buy and a relatively strong Mojo Score of 72.0 indicate underlying fundamental strength. Investors may view the current weakness as a potential entry point, provided the broader sector environment stabilises and company-specific catalysts emerge.

However, caution is warranted given the stock’s recent downgrade from Strong Buy and the evident short-term technical weakness. Market participants should closely monitor volume patterns, price action around key moving averages, and sector news to gauge the sustainability of any recovery.

Summary

Venus Remedies Ltd’s stock experienced a significant setback on 12 Jan 2026, hitting its lower circuit limit amid heavy selling pressure and heightened volatility. The stock underperformed its sector and the Sensex, reflecting investor apprehension and a shift in sentiment. While the company retains a favourable Mojo Grade and score, the immediate outlook is clouded by technical weakness and unfilled supply. Investors should remain vigilant and consider both fundamental and technical factors before making decisions.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →